MetGen
METGEN designs and markets novel enzymatic solutions for customers working in bio-based materials. MetGen, founded in 2008 and is based in Kaarina, Finland, creates industrial, highly-active, natural catalysts that accelerate chemical reactions. The company uses advances in genetic engineering and microbiology to adapt enzymes to harsh industrial conditions and to handle a variety of lignocellulosic substrates. MetGen aims to be a widely recognized supplier of industrial enzymes, significantly contributing to the economics and sustainability of process industries such as biofuels and renewable chemicals.
Sector
Industrial Biotech
Strategies
Industrial Biotech
Status
Live
Website
www.metgen.com
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.